Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Trial Profile

Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Melanoma-associated-antigen-A4-specific-T-cells-Adaptimmune (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Bladder cancer; Gastric cancer; Head and neck cancer; Large cell carcinoma; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Synovial sarcoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Adaptimmune
  • Most Recent Events

    • 04 Feb 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2035.
    • 06 Nov 2018 According to an Adaptimmune media release, the Safety Review Committee (SRC) has agreed to move into the expansion phase.
    • 08 Oct 2018 According to an Adaptimmune media release, data from this study were presented at the European Society for Medical Oncology (ESMO) 2018 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top